Upadacitinib in moderate to severe atopic dermatitis: High doses produce added benefit for adults
Upadacinib is a new drug for the treatment of adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy. In an early benefit assessment, the German Institute ...
Dec 9, 2021
0
4